GlassScriptPhysician profile
Shivani Sheth
NPI 1184454324
$1,159.55
in general payments reported to CMS, 2019-2025
15 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $239.60 | 2025 | Tremfya, Simponi, Simponi Aria |
| Aimmune Therapeutics, INC. | $121.04 | 2025 | Zenpep |
| Ardelyx, INC. | $96.43 | 2025 | Ibsrela |
| Abbvie INC. | $89.46 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $80.50 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $77.84 | 2025 | Rezdiffra |
| Celltrion USA INC. | $70.00 | 2025 | Vegzelma |
| Pfizer INC. | $64.99 | 2025 | |
| Intercept Pharmaceuticals, INC. | $64.27 | 2025 | |
| Genzyme Corporation | $61.16 | 2025 | |
| Phathom Pharmaceuticals, INC. | $56.03 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $45.12 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $38.60 | 2025 | Entyvio |
| Gilead Sciences, INC. | $27.30 | 2025 | |
| Qol Medical, LLC | $27.21 | 2025 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivani Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.